COVID-19 vaccine Ad26.COV2.S

A coronavirus vaccine composed of a genetically engineered, replication-incompetent, adenovirus serotype 26 (Ad26) vector expressing the stabilized pre-fusion spike (S) protein of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), with potential immunomodulating and anti-COVID-19 activities. Upon intramuscular administration of the COVID-19 vaccine Ad26.COV2.S, the Ad26 infects human cells, which produces SARS-CoV-2 S protein. The released S protein activates the immune system to induce a humoral and cell-mediated immune response against SARS-CoV-2. This may prevent SARS-CoV-2 infection and inhibit viral replication. S protein, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.